Trisomy 12 (tri12) is the second most frequent chromosomal aberration (15%-20%) in chronic lymphocytic leukemia (CLL). Tri12 confers an intermediate prognosis but is a heterogeneous entity. We examined whether additional mutational or chromosomal alterations might impact tri12 patient outcomes. This retrospective study, carried out by the French Innovative Leukemia Organization, included 188 tri12 patients with comprehensive information on immunoglobulin heavy chain (IGHV) gene status, karyotypic/FISH abnormalities, and NOTCH1, TP53, SF3B1, and MYD88 mutations. The main cytogenetic abnormalities associated with tri12 were del(13q) (25%), additional trisomies (14%) (including tri19 (10%) and tri18 (4%)), 14q32 translocations (10%), del(17p) (6.5%), del(14q) (4%), and del(11q) (4%). Unmutated (UM) IGHV, NOTCH1, and TP53, mutations were identified in respectively 66%, 25%, and 8.5% of cases. Multivariate analyses showed that additional trisomies (HR = 0.43, 95% CI = 0.23-0.78, P = .01) were associated with a significantly longer time to first treatment in Binet stage A patients and with a lower risk of relapse (HR = 0.37, 95% CI = 0.15-0.9, P = .03) in the overall tri12 population. Binet stage B/C, TP53 disruption, and UM IGHV status were associated with a shorter time to next
treatment, while Binet stage B/C (HR = 4, 95% CI = 1.6-4.9, P = .002) and TP53 disruption (HR = 5, 95% CI = 1.94-12.66, P = .001) conferred shorter overall survival in multivariate comparisons. These data indicate that additional cytogenetic and mutational abnormalities, and particularly additional trisomies, IGHV status, and TP53 disruption, influence tri12 patient outcomes and could improve risk stratification in this population.
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| INTRODUCTION
The clinical course of chronic lymphocytic leukemia (CLL) is highly variable, ranging from very stable disease with near-normal life expectancy to rapidly progressive disease that requires treatment. 1, 2 Features known to influence the disease course include somatic mutations of immunoglobulin heavy chain (IGHV) genes, recurrent chromosomal abnormalities (CAs), and gene mutations such as inactivating mutations of TP53 and ATM. Recently, several large studies based on massive next-generation sequencing (NGS) [3] [4] [5] [6] [7] [8] [9] [10] have provided a more detailed genetic picture of CLL, revealing recurrent mutations in other genes such as SF3B1, NOTCH1, EGR2, NFKBIE, XPO1, and MYD88, some being associated with aggressive disease. 11, 12 Among the recurrent cytogenetic abnormalities associated with CLL, trisomy 12 (tri12) occurs in approximately 15%-20% of cases. 13, 14 Other common CAs identified by means of conventional and molecular cytogenetic approaches include del (13)(q14), del (11)(q22-23), del (17) (p13), gain (2)(p), and del (6)(q21). These alterations influence survival. [14] [15] [16] [17] Tri12 was usually considered to be an intermediate-risk
genetic lesion in newly diagnosed CLL and in the context of chemotherapy treatment, 14 although recent reports suggest that it confers more complex and heterogeneous clinical behavior. 18 Indeed, accompanying chromosomal aberrations such as additional trisomies (tri18 and/or tri19), [18] [19] [20] 14q32 translocations (t [14;18] (q32;q21) and t (14, 19 )(q32; q13)), [21] [22] [23] [24] [25] and 14q deletions 26, 27 are commonly observed in tri12 CLL, and it has been suggested that patients harboring additional trisomies have better outcomes than patients with isolated tri12. 18 Compared to CLL lacking this cytogenetic abnormality, tri12 CLL has a more atypical morphology and immunophenotype, 28, 29 more frequent expression of the poor prognostic markers CD49d and CD38, more frequent NOTCH1 mutations, and unmutated (UM) IGHV gene status. 27, 30, 31 Recent NGS analyses show that the CLL genome displays a high degree of heterogeneity, both across patients and in a given patient. [8] [9] [10] Among somatic genetic alterations, copy-number abnormalities may be the earliest events in CLL, with two distinct points of departure involving del(13q) and tri12. 8, 9 Tri12 is thus usually considered to be a clonal driver lesion occurring early in the course of CLL, and additional molecular and/or cytogenetic abnormalities could explain in part why it is a heterogeneous entity and why its prognostic value is controversial.
The aim of this study was to determine whether additional molecular and cytogenetic abnormalities could impact the outcome of tri12 CLL. 
| MATERIAL AND METHODS

| Patients
| Cytogenetic and mutational analyses
CB analysis was performed as previously described, 27 with CpG oligonucleotides and interleukin 2 stimulation. 3 | RESULTS
| Patient characteristics
The study population comprised 188 untreated patients. Respectively 120 and 68 patients had stage A and stage B/C CLL. B2M was above 4 mg/L in 46/152 patients (32%) and IGHV status was unmutated (UM) in 66% of cases (Table 1) . Median follow-up of the whole cohort was 78 months (range, 1-397). with UM compared to mutated IGHV cases while there was no Table 2 . Of note, UM IGHV cases were significantly less frequent in the subgroups with additional trisomies and 14q32 translocations. NOTCH1 mutations were associated with UM IGHV (respectively 31% and 14% of NOTCH1 mutations in UM and M IGHV cases; P = .02) and there was a trend for an association between TP53 disruption and IGHV status as respectively 15%
| Cytogenetic and molecular features
and 8% of UM and mutated IGHV cases were TP53 disrupted (P = .07).
| Outcomes
In Statistical comparisons were performed between the population carrying the abnormality and the population without that abnormality. Differences were considered significant when P value was inferior or equal to .05. Abbreviations: CA, chromosomal abnormalities; CB, chromosome banding; n, number; P, P value; UM, unmutated The second column represents for each variable the number of events and the total number of samples assessable for. Lymphocytosis, age, and percent of tri12 were studied as continuous variables. The percent of tri12 corresponds to the percentage of interphase nuclei harboring trisomy 12 by FISH. Of note, as MYD88 mutations have been associated with good prognosis, we performed statistical analysis excluding, from the "any mutation" group, patients harboring those mutations (n = 2) and observed similar associations with survival (data not shown). Abbreviations: B2M, beta2microglobuline; CI, confidence interval; HR, hazard ratio; NS, non significant Table S1 ). Binet stage B/C and TP53 disruption were also associated with a shorter TNT in multivariate analysis, as was UM IGHV status (Table 4 The second column represents for each variable the number of events and the total number of samples assessable for. Lymphocytosis, age, and percent of tri12 were studied as continuous variables. The percent of tri12 corresponds to the percentage of interphase nuclei harboring trisomy 12 by FISH. Of note, as MYD88 mutations have been associated with good prognosis, we performed statistical analysis excluding, from the "any mutation" group, patients harboring those mutations (n = 2) and observed similar associations with survival (data not shown). Abbreviations: B2M, beta2microglobuline; CI, confidence interval; HR, hazard ratio; NS, non significant Lymphocytosis is studied as a continuous variable. The percent of tri12 corresponds to the percentage of interphase nuclei harboring trisomy 12 by FISH.
Of note, as MYD88 mutations have been associated with good prognosis, we performed statistical analysis excluding, from the "any mutation" group, patients harboring those mutations (n = 2) and observed similar associations with survival (data not shown). Abbreviations: B2M, beta2microglobuline; CI, confidence interval; HR, hazard ratio; K, karyotype; NS, non significant patients with tri12, notably those with additional trisomies (tri18 and tri19), [18] [19] [20] 14q32 translocations, 21, 22 or del(14q). 26, 27 Recent NGS studies have also highlighted the prognostic impact of some recurrent gene mutations, such as those affecting TP53, NOTCH1, and SF3B1. A study of more than 1000 newly diagnosed and untreated CLL patients
showed that the integration of mutational and cytogenetic data could improve the classical FISH-based hierarchical model, by reclassifying patients who harbored NOTCH1, SF3B1, TP53, and/or BIRC3 mutations into higher risk groups. 33 Studies of tri12 populations integrating comprehensive karyotype/FISH data and mutational information are scarce. Our study included exhaustive cytogenetic data, IGHV status, and a search for several recurrent and high-risk genetic mutations in order to refine outcome prediction in a retrospective multicentre cohort of tri12 patients. Two-thirds of the patients were UM IGHV, and the frequencies of the main cytogenetic abnormalities were concordant with previous reports: del(13q) (18%-25%), del(11q) (4%-8%), del(17p) (5%-7%), and additional trisomies (12%-13%). 31, 34 In agreement with previous studies, we also found that NOTCH1 mutations were associated with UM IGHV and were the most recurrent mutations (25%), followed by TP53 mutations (8.5%), while SF3B1 and MYD88 mutations were rare (<5%). 18, 31, 34, 35 In addition to classical prognostic factors (age and Binet stage), certain cytogenetic and molecular features impacted the outcome of tri12 CLL patients in our cohort. Indeed, additional trisomies were significantly associated with a longer TFT and a lower relapse rate, while TP53 disruption correlated with a higher risk of relapse, shorter TNT, and shorter OS.
Regarding recurrent cytogenetic abnormalities, the presence of concurrent trisomies has been linked to particular clinical-biological profiles. 18, 34, 36 The two most recurrent trisomies associated with tri12 are tri18 and tri19. 18, 20 The presence of concurrent tri19 has been shown to confer a better prognosis compared to isolated tri12, 18 while tri18 is rarely isolated, mostly associated with tri19 and considered as a subclonal event. 20, 36 In our series, all cases harboring tri18 except one were indeed associated with tri19. Tri19 was associated with longer TFT (HR = 0.22, 95% IC 0.08-0.62, P = .004), lower rate of relapse (HR = 0.14, 95% IC 0.03-0.52, P = .007) and a trend to longer TNT (HR = 0.13, 95% IC 0.02-1.03, P = .053) in univariate analysis but did not retain prognostic significance in multivariate analyses while additional trisomies taken as a whole were significantly associated with longer TFT and lower relapse rate (Table 3 and Supporting Information Table S1 ). IGHV mutational status was recently shown to be the strongest prognostic factor in a cohort of tri12 patients, 35 after exclusion of TP53 disrupted and del(11q) cases. In our series, in which these latter cases were not excluded, IGHV mutational status impacted the relapse rate, TNT, and OS, but not TFT, in univariate analyses (Supporting Information Figure S3 ). However, IGHV mutational status only retained significance for TNT in multivariate analysis. We also examined whether additional trisomies and NOTCH1 mutations could stratify mutated and UM IGHV cases, respectively (Supporting Information Figure S4 ). Interestingly, additional trisomies positively impacted TFT and TNT in IGHV mutated patients, while NOTCH1 mutations had no impact on the outcome of UM IGHV patients. Thus, tri12 patients harboring mutated IGHV and additional trisomies display a very indolent clinical course, raising the question of the potential interest of performing CB to identify this particular population.
The differences between our results and previous reports might be due in part to differences in the exhaustiveness of the cytogenetic and molecular abnormalities examined. Of note, the distribution of mutations varies among different cytogenetic groups (Table 2 and 
